Cojocaru, Elena
Wilding, Christopher
Engelman, Bodil
Huang, Paul
Jones, Robin L.
Article History
First Online: 11 January 2020
Compliance with Ethical Standards
:
: Elena Cojocaru declares nothing to disclose.Christopher Wilding declares nothing to disclose.Bodil Engelman declares nothing to disclose.Paul Huang declares nothing to disclose.Robin L. Jones is a consultant for Adaptimmune, Athenex, Blueprint, Clinigen, Eisai, Epizyme, Daichii, Deciphera, Helsinn, Immunedesign, Lilly, Merck, Pharmamar, Tracon, and UpToDate and a current investigator on the phase 2 trial of IDH1 inhibitor sponsored by Forma Therapeutics.